[1] European Association for the Study of the Liver (EASL);European Association for the Study of Diabetes (EASD);European Association for the Study of Obesity(EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Obes Facts,2016,9:65-90.
[2] Lonardo A,Ballestri S,Marchesini G,et al.Nonalcoholic fatty liver disease:a precursor of the metabolic syndrome. Dig Liver Dig,2015,47:181-190.
[3] Eslam M,Geoyge J.Genetic and epigenetic mechanisms of NASH. Hepatol Int,2016,10:394-406.
[4] Xiong J,Wang J,Huang J,et al.Non-alcoholic steatohepatitis-related liver cirrhosis is increasing in China :a ten-year retrospective study. Clinics (Sa0Paulo),2015,70:563-568.
[5] Hartieb M,Baranski K,Zejda J,et al.Non-alcoholic fatty liver (NAFL) and advanced fibrosis in the elderly:results from a community-based Polish survey. Liver Int,2017,[Epub ahead of print].
[6] Kabbany MN,Conjeevaram Selvakumar PK,Watt K,et al.Prevalence of nonalcoholic steatohepatitis-associated cirrhosis in the United States:analysis of National Helath and Nutrition Examination Survey Data. Am J Gastroenterol,2017,112:581-587.
[7] Xong J,Wang J,Huang J,et al.Non-alcoholic steatohepatitis-related liver cirrhosis is increasing in China:a ten-year retrospective study. Clinics (Sao Paulo),2015,70:563-568.
[8] Arab JP,Barrera F,Gallego C,et al.High prevalence of undiagnosed liver cirrhosis and advanced fibrosis in type2 diabetic patients. Ann Hepatol,2016,15:721-728.
[9] Bhadoria AS,Kedarisetty CK,Bihari C,et al. Impact of family history of metabolic traits on severity of non-alcoholic steatohepatitis related cirrhosis:A cross-sectional study. Liver Int,2017 Feb 23,[Epub ahead of print].
[10] Oxley SM,Sackstein R.Detect of an L-selectin ligand on a hematopoietic progenitor cell line. Blood,1994,84:3299-3306.
[11] Alves CS, Burdick MM,Thomas SN,et al.The dual role of CD44 as a functional P-selectin ligand and fibrin receptor in colon carcinoma cell adhesion. Am J Physiol,Cell Physiol,2008,294:C907-916.
[12] Patouraux S,Rousseau D,Bonnafous S,et al. CD44 is a key player in non-alcoholic steatohepatitis. J Hepatol,2017 Mar 16,[Epub ahead of print].
[13] Laish I,Mannasse-Green B,Hadary R,et al.Telomere dysfunction in nonalcoholic fatty liver disease and cryptogenic cirrhosis. Cytogenrt Genome Res,2016,150:93-99.
[14] Petta S,Valenti L,Svegliati-Baroni G,et al.Fibronectin type III domain-containing protein 5 re3480AG polymorphism,irisin,and liver fibrosis in patients with nonslcoholic fatty liver disease. J Clin Endocrinol Metab,2017,[Epub ahead of print].
[15] Nakajima S,Tanaka H,Sawada K,et al.Polymorphism of receptor-type tyrosine-protein phosphatase delta gene in the development of non-alcoholic fatty liver disease. J Gastroenterol Hepatol,2017,[Epub ahead of print].
[16] Kim SG,Kim BK,Kim K,et al.Bile acid nuclear receptor Farnesoid X receptor:therapeutic target for noncoholic fatty liver disease.Endocrinol Metab (Seoul),2016,31:500-504.
[17] Zhu Y,Liu H,Zhang M,et al.Fatty liver diseases,bile acids,and FXR. Acta Pharm Sin B,2016,6:409-412.
[18] de la Garza RG,Morales-Garza LA,Martin-Estal I,et al. Insulin-like growth factor-1 deficiency and cirrhosis establishment. Clin Med Res,2017,9:233-247.
[19] Chishima S,Kogiso T,Matsushita N,et al.The relationship between the growth hormone/insulin-like growth factor system and the histological features of noncoholic fatty liuver disease. Intern Med,2017,56:473-480.
[20] Chimen M,Yates CM,McGettrick HM,et al. Monocyte subsets coregulate inflammatory responses by integrated signaling through TNF and IL-6 at the endothelial cell interface. J Immunol,2017,198:2834-2843. |
